Log in

Endpoints News Announces the 11 Most Promising Biotech Startups of 2022

Posted

LAWRENCE, Kan.--(BUSINESS WIRE)--Sep 22, 2022--

Endpoints News, the biopharma industry’s leading source for daily news and analysis, today unveiled the 2022 Endpoints 11 — the most promising biotech startup companies of the year.

Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. This year’s list of Endpoints 11 winners is comprised of companies most likely to make their mark — or go down fighting for a landmark change.

"I've been picking top biotech startups for 20 years now, and every year's class of standouts is different in its own way. This group faces some unusual challenges,” said John Carroll, founder and editor of Endpoints News. “But they all have substantial resources, top talent and plans to tackle some of the biggest challenges in biotech. They may not all make it — that doesn't happen often — but their ambitions define the industry today. And that's what the Endpoints 11 is all about.”

The 2022 Endpoints 11 winners are:

  • Affini-T
  • Altos Labs
  • Areteia Therapeutics
  • Generate Biomedicines
  • Mammoth Biosciences
  • Metagenomi
  • Neumora Therapeutics
  • Odyssey Therapeutics
  • Orna Therapeutics
  • Rome Therapeutics
  • Versanis Bio

The 2022 Endpoints 11 will be hosted live at The 105 in Boston with an open bar and networking beginning at 6 pm ET. At 7 pm ET, Carroll will visit with Nobel Prize laureate and biotech legend Phillip Sharp in an exclusive fireside chat. “Sharp was present at the creation of the biotech industry, which has blossomed into a global endeavor that’s seen investors pile in as startups tackled some of the biggest challenges in drug hunting,” said Carroll.

At 7:30 pm ET, Alessandro Maselli, President & CEO at Catalent, will present the awards alongside Carroll. Attendees will also see exclusive footage of Carroll talking biotech with the teams behind the Endpoints 11. The event is sponsored by Catalent, Egnyte and Precision ADVANCE, the cell & gene therapy collective and will be live-streamed to registrants from 7 to 8:15 pm ET.

This marks John Carroll’s 20th year selecting top private biotechs for special recognition. Registration is open to all biopharma professionals at eleven22.endpts.com. Ticket sales for the live event will close at 4 pm ET today. The web feature with profiles on each company is available to Endpoints readers with a premium subscription at www.endpts.com.

About Endpoints News

Endpoints News is an independent media company covering the most influential developments across the life sciences industry. Founded in 2016 by award-winning editor John Carroll and publisher Arsalan Arif, the publication has attracted a global team of more than 40 writers and media professionals, delivering readers the critical insights they need, when they need them the most. Breaking news, industry analysis and in-depth journalism are delivered daily through the industry’s most comprehensive news reports. The top destination for life sciences news, Endpoints is read by key decision-makers changing the future of healthcare. With a growing readership of 150,000 subscribers, Endpoints News has earned more than 4 million page views a month, with around 1 million readers that include leaders from the most innovative startups to the top 25 large pharma companies. Endpoints News is a virtual company with corporate headquarters in Lawrence, Kansas. For more information, visit www.endpts.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220922005034/en/

CONTACT: Media:

Amanda Florez

Endpoints News

aflorez@endpointsnews.com

KEYWORD: MASSACHUSETTS KANSAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH START-UP MEDIA COMMUNICATIONS HEALTH TECHNOLOGY PROFESSIONAL SERVICES

SOURCE: Endpoints News

Copyright Business Wire 2022.

PUB: 09/22/2022 07:00 AM/DISC: 09/22/2022 07:03 AM

http://www.businesswire.com/news/home/20220922005034/en